SITC 2022 TiP: Tacti-003

TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Background:

Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen-presenting cell (APC) and then CD8 T-cell activation. Data from a non-randomized, phase II trial of efti plus pembrolizumab (TACTI-002) showed encouraging antitumor activity and manageable safety when given as second-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). TACTI-003 (NCT04811027) is a multicenter, open-label, randomized phase II trial to investigate efti plus pembrolizumab in the first line setting for RM-HNSCC.

Methods:

A total of 154 patients (pts) are currently being recruited into two cohorts (A+B). In cohort A, pts with tumors that are CPS≥1 will be randomly assigned 1:1 to receive either efti (30 mg subcutaneously Q2W for initial 6 months, thereafter Q3W) plus pembrolizumab (400 mg intravenously Q6W) for up to two years or pembrolizumab alone. Randomization will be stratified by CPS (1-19 vs. ≥ 20) and ECOG PS (0 vs. 1). Pts with tumors that are CPS<1 will receive efti plus pembrolizumab (cohort B). Imaging will be performed every 9 weeks. The primary endpoint (EP) is the objective response rate (ORR) by RECIST1.1. Secondary EPs include overall survival, ORR according to iRECIST, time to and duration of response, disease control rate, progression-free survival, the occurrence of anti-efti -specific antibodies, safety, and quality of life. Exploratory endpoints comprise biomarkers.

Authors: Braña I1; Cheshuk V2; Andrup Kristensen C3; Eugenia Ortega M4; Sautois B5; López-Pousa A6; Christian J7; Lybaert W8; Peguero J9; Park J10; Metcalf R11; Nabell L12; Doger B13; Rubió Casadevall J14; Soria Rivas A15; Forster M16; Triebel F17

Affiliates:

1- Braña: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
2- Cheshuk: ARENSIA Exploratory Medicine LLC, Kyiv, Ukraine
3- Andrup Kristensen: Rigshospitalet; Copenhagen, Denmark
4- Eugenia Ortega: Hospital Universitario Miguel Servet, Zaragoza, Spain
5- Sautois: Centre Hospitalier Universitaire (CHU) de Liege; Liège, Belgium
6- López-Pousa: Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain
7- Christian: Nottingham University Hospitals, NHS Trust, Nottingham, United Kingdom
8- Lybaert: VITAZ, Sint-Niklaas, Belgium
9- Peguero: Oncology Consultants, P.A., Houston, USA
10- Park: Macquarie University Hospital, Macquarie Park, NSW, Australia
11- Metcalf: The Christie NHS Foundation Trust, Manchester, United Kingdom
12. Nabell: University of Alabama at Birmingham (UAB) - O’Neal Cancer Center, Birmingham, United States
13. Doger: START Madrid (Hospital Universitario Fundación Jiménez Díaz), Madrid, Spain
14. Rubió Casadevall: Institut Català d’Oncologia - Hospital Universitari de Girona, Girona, Spain
15. Soria Rivas: Hospital Universitario Ramón y Cajal, Madrid, Spain
16. Forster: UCL Cancer Institute; University College London Hospitals NHS Foundation - The Harley Street Clinic, London; United Kingdom
17. Triebel: Research & Development, Immutep S.A.S., Orsay, France